MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine

Summary

First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg

Timeline

Start

2021-12-01

Primary completion

2022-08-03

Completion

2023-05-09

Drugs

Indications